Strategic Collaborations, a New Trend to Extract the Maximum out of ADCs
Antibody Dug Conjugates have been attracting a lot of interest from researchers and pharma giants across the world. This surge in interest can be attributed to improved technologies that have enhanced the potential of ADCs. Pharma giants are indulging in strategic moves such as collaborations, mergers and acquisitions, being made in order to combine technologies and capabilities from other companies with inherent ones for the development of ADCs. For example, Sorrento Therapeutics recently acquired Concortis Biosystems, a deal which will...
View full press release